Request Demo
Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors
License out/inADC
INCHEON, Korea & SHANGHAI--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the companies have entered into a global collaboration agreement to develop, manufacture and commercialize two ADC assets: TJ108, bispecific and dual-payload ADC, and another asset to be named. In addition, Samsung Bioepis will receive an exclusive license from Phrontline for one topoisomerase-1 inhibitor (TOP1i) payload which is applied to Samsung Bioepis’ ADC pipeline.
We are excited to partner with Phrontline in developing and advancing differentiated ADCs that target a broad range of indications.
Phrontline’s TJ108 is TOP1i and tubulin inhiSamsung Bioepis Co., Ltd.againPhrontline BiopharmaFactor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 3 (HER3), targets that are overexpressed in a variety of cancers, which contribute to aggressive growth and metastasis.i,iiADCTJ108ADCSamsung BioepisPhrontlinetopoisomerase-1 inhibitor (TOP1i)Samsung BioepisADC
Under the terms of the agreemenPhrontlineine will receive an upfront payment and will be eligible to receive additional milestone payments tied to development and regulatory achievements.
PhrontlinecitTJ108 partner with tubulin inhibitor-based ADCtubulinine in developing and advancing differEpidermal Growth Factor Receptor (EGFR) of iHuman Epidermal Growth Factor Receptor 3 (HER3)hief Executive Officer, at Samsung Bioepis. “We wcancerstinue to explore new business opportunities to address unmet needs of patients, leveraging our proven development platforms.”
“Phrontline has honed its bispecifPhrontlineng technology to enhance payload delivery efficiency and has advanced an innovative dual-linker payload (DLP) platform that enables the simultaneous delivery of two payloads with balanced potency and distinct mechanisms of action through a branched-linker architecture, while supporting scalable and efficient one-step conjugation. This partnership accelerates our vision to establish bispecific, dual-payload ADCs as a new class of precision oncology medicines,” said Zhaoyuan ‘Tony’ Chen, Founder and Chief Executive Officer of Phrontline Biopharma. “Together with Samsung Bioepis, we will scale the DLP platform — beginning with TJ108 — to address resistance, heterogeneity, and durability challenges that limit today’s single-payload, single-target ADCs.”
Samsung Bioepis is expanding itsPhrontlinebeyond biosimilars to fulfill its mission of broadening patient access to treatments in the areas of unmet therapeutic needs. The development of ADCs couSamsung Bioepis company’s broad spectrum of therapeutic portfolio that covers immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology.
APhrontlineng Bioepis Co., Ltd.Phrontline BiopharmaSamsung BioepisTJ108
Samsung Bioepis2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – X, LinkedIn.
Phrontline Biopharma Samsung Bioepistage biotechnology company headquartered in Suzhou, China. The company’s mission is to develop a new class of bispecific, dual-payload antibody–drug conjugates (ADCs) designedSamsung Bioepise limitations of single-payload, single-target ADCs—particularlSamsung Bioepis resistance, tumor heterogeneity, and durability of response.
PhrontPhrontline Biopharma proprietary bispecific antibody and dual-linker payload (DLP) platforms that enhance payload delivery efficiency and enable the simultaneous delivery of two payloads with balanced potency and complementary mechanisms of action through a branched-linker architecture. The company is dedicated to advancing more effective and durable treatment options for patients with high unmet medical needs through its in-house innovation and integrated technology platforms.
Phrontline Biopharma, please visit www.PhrontlineBio.com and follow us on LinkedIn.tumor
Phrontlineka J, Karaś K, Karwaciak I, Ratajewski M. Targeting egfr in melanoma – the sea of possibilities to overcome drug resistance. Biochim Biophys Acta (BBA) - Rev Cancer. (2022) 1877:188754. doi: 10.1016/j.bbcan.2022.188754
ii Papa F, Grinda T, Rassy E, et al. Long road towards effective HER3 targeting in breast cancer. Cancer Treat Rev. 2024;129:102786. doi: 10.1016/j.ctrv.2024.102786
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Drugs
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!